Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

Kim Papp; Herve Bachelez; Antonio Costanzo; Peter Foley; Melinda Gooderham; Primal Kaur; Joanna Narbutt; Sandra Philipp; Lynda Spelman; Jolanta Weglowska; Nan Zhang; Bruce Strober

doi:10.1016/j.jaad.2016.12.014

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.12.014 ◽

2017 ◽

Vol 76 (6) ◽

pp. 1093-1102 ◽

Cited By ~ 51

Author(s):

Kim Papp ◽

Herve Bachelez ◽

Antonio Costanzo ◽

Peter Foley ◽

Melinda Gooderham ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Multicenter Phase ◽

Phase Iii Study ◽

Abp 501

Download Full-text

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis

British Journal of Dermatology ◽

10.1111/bjd.15857 ◽

2017 ◽

Vol 177 (6) ◽

pp. 1562-1574 ◽

Cited By ~ 29

Author(s):

K. Papp ◽

H. Bachelez ◽

A. Costanzo ◽

P. Foley ◽

M. Gooderham ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Long Term Results ◽

Double Blind ◽

Phase Iii Trial ◽

Severe Plaque Psoriasis ◽

Randomized Controlled ◽

Single Transition ◽

Abp 501

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicenter, Phase III Study

Clinical Therapeutics ◽

10.1016/j.clinthera.2017.08.013 ◽

2017 ◽

Vol 39 (10) ◽

pp. 2049-2060 ◽

Cited By ~ 2

Author(s):

Soon Jun Hong ◽

Han Saem Jeong ◽

Seung Hwan Han ◽

Ki Yuk Chang ◽

Bum Kee Hong ◽

...

Keyword(s):

Phase Iii ◽

Losartan Potassium ◽

Fixed Dose ◽

Double Blind ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Cited By ~ 49

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Sa1217 Once Daily Dosing of 9mg Budesonide (Budenofalk®) Is Therapeutic Equivalent to a Three-Times Daily Dosing of 3mg Budesonide for the Treatment of Active Crohn's Disease: A Randomized, Double-Blind, Double-Dummy, Multicenter Phase III Study

Gastroenterology ◽

10.1016/s0016-5085(13)60823-9 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-233 ◽

Cited By ~ 1

Author(s):

Axel U. Dignass ◽

Simeon Stoynov ◽

Andrey E. Dorofeyev ◽

Galina A. Grigorieva ◽

Eva Tomsova ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Phase Iii ◽

Double Blind ◽

Once Daily ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

British Journal of Dermatology ◽

10.1111/bjd.14493 ◽

2016 ◽

Vol 175 (2) ◽

pp. 273-286 ◽

Cited By ~ 213

Author(s):

K.A. Papp ◽

K. Reich ◽

C. Paul ◽

A. Blauvelt ◽

W. Baran ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Prospective Phase

Download Full-text

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

Pituitary ◽

10.1007/s11102-014-0585-6 ◽

2014 ◽

Vol 18 (3) ◽

pp. 385-394 ◽

Cited By ~ 40

Author(s):

Michael Sheppard ◽

Marcello D. Bronstein ◽

Pamela Freda ◽

Omar Serri ◽

Laura De Marinis ◽

...

Keyword(s):

Phase Iii ◽

Extension Phase ◽

Double Blind ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, Phase III study

Endocrine Abstracts ◽

10.1530/endoabs.32.p847 ◽

2013 ◽

Cited By ~ 3

Author(s):

Pamela Freda ◽

Maria Fleseriu ◽

der Lely Aart Jan van ◽

Annamaria Colao ◽

Michael Sheppard ◽

...

Keyword(s):

Phase Iii ◽

Biochemical Control ◽

Double Blind ◽

Octreotide Lar ◽

Multicenter Phase ◽

Phase Iii Study

Download Full-text

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

BioDrugs ◽

10.1007/s40259-021-00502-w ◽

2021 ◽

Author(s):

Steven R. Feldman ◽

Nataliya Reznichenko ◽

Grazyna Pulka ◽

Külli Kingo ◽

George Galdava ◽

...

Keyword(s):

Active Control ◽

Plaque Psoriasis ◽

Phase Iii ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Control Phase ◽

Parallel Group ◽

Phase Iii Study

Download Full-text